Abingdon Health to expand manufacturing capacity on back of increased demand for rapid tests

Abingdon Health will expand its York headquarters in the UK, following further investment in state-of-the-art lateral flow automation. This will substantially increase in its manufacturing footprint, resulting in Europe’s largest capacity for rapid test manufacturing, according to the company.

Abingdon Health is a technology-enabled lateral flow diagnostics company providing innovative rapid testing solutions to a multi-industry, global client base. The company provides specialist assay development and smartphone reader solutions alongside its lateral flow test manufacturing capacity.

The announcement of the expansion comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium.

Michael Hunter, Operations Director of Abingdon Health, commented: “The additional footprint and automation come at a timely moment as demand for rapid tests is growing rapidly, with the market likely to exceed US$10bn globally. Our precision automation and multi-site approach means we can adapt to meet the varying manufacturing needs of our growing global client base.”

Earlier this year, Abingdon Health announced a preliminary round of expansion in York after 90% revenue growth in 2019, thanks to new assay developments and assay manufacturing contract wins, and the introduction of its AppDx Smartphone reader software. In April 2020, growth continued with the acquisition of a new lateral flow manufacturing facility in Doncaster, UK. This latest expansion and investment in equipment comes as 2020 sees continuing high demand for Abingdon Health’s services.

Abingdon Health’s two manufacturing sites in York and Doncaster have the capacity to produce millions of rapid tests per month. This adaptable, dual-site approach provides a peace-of-mind solution that assures customers receive product consistency and a security of supply during routine scheduling and spikes in demand.